The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The FDA has granted accelerated approval to IMDELLTRA™ for treating extensive-stage small cell lung cancer following platinum ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung ...
Schedule one drugs, such as heroin, are considered highly addictive with no medical benefits, while schedule three drugs are ...
The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its ...
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung ...
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...
Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.